Seeing with new eyes: Finding a path to early intervention trials in Alzheimer's disease

Journal of Nutrition, Health and Aging

Volumn 14, Issue 4, 2010, Pages 306-309

  Cedarbaum, J M ^a   Crans, G ^a   Grundman, M ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Biomarkers; CDR; Mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE;

ALGORITHM; ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE SEVERITY; EARLY INTERVENTION; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLINICAL TRIAL (TOPIC); COGNITION DISORDERS; PATIENT SELECTION; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ALGORITHMS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951780844     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-010-0069-y     Document Type: Article

References (33)

1. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al. Current Concepts I Mild Cognitive Impairment. Arch Neurol 2001;58:1985-1992.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
4. Petersen RC, Morris JC. Mild Cognitive Impairment as a Clinical Entity and Treatment Target Arch. Neurol 2005,62:1160-1163.
5. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197-2204.
6. Petersen, RC. Early Diagnosis of Alzheimer's disease: Is MCI too late? Current Alzhimer's Research 2009; 6:324-330.
7. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, et al. Longitudinal stability of CSF tau levels in Alzheimer subjects. Biol Psychiatry. 1999 15; 46:750-755.
8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
9. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
10. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
11. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij, Darcourt J. Sensitivity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-313.
12. Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603-609.
13. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213:315-325.
14. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007 :734-746.
15. Dubois B. 'Prodromal Alzheimer's disease': a more useful concept than mild cognitive impairment? Curr Opin Neurol. 2000;13:367-369.
16. Frisoni GB, Padovani A, Wahlund LO. The predementia diagnosis of Alzheimer disease. Alzheimer Dis Assoc Disord. 2004;18:51-53.
17. Morris JC, McKeel DW, Sorandt M, Rubin EH, Price JL, Grant MJ et al. Very mild Alzheimer's disease: Informant-based clinical, psychometric and pathologic distinction from normal aging. Neurology 1991; 41:463-1448
18. Bennett DA. Existing Evidence for Presymptomatic and Preclinical AD: What is AD and when does it begin? Presented at the Alzheimer's Association Research Roundtable, "Early Risk Assessment for Alzheimer's Disease". Washington, DC. November 13, 2007.
19. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.Ann Neurol. 2009,65:403-1113
20. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
21. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294-301.
22. Committee for Medicinal Products for Human Use (CHMP). Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use. London, 24 July 2008. Doc. Ref. CPMP/EWP/553/95 Rev.1.
23. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of AD immunization (AN1792) in subjects with AD in an interrupted trial. Neurology 2005; 64:1553-1562.
24. Harrison J, Minassian SM, Jenkins L, Black RS, Koller M, Grundman M. The NTB: A neuropsychological test Battery for Use in Alzheimer's Disease Clinical Trials. Arch Neurol 2007 64:1323-1329.
25. Grundman M, Black R, Liu E, Motali R, Zawadzki R, McLaughlin T. The Neuropsychological Test Battery discriminates patients with Mild Cognitive Impairment from normal controls and Alzheimer's disease. Alzheimer's & Dementia 2008;4:T560.
26. Fahn S, Elton RI, UPDRS Program Members. Unified Parkinson's disease rating scale. In: Fhn, S. Marsden CD, Goldstein M, Calne DB (eds)-. Recent developments in Parkinsons' Disease, Vol.2. Florham Park NJ: Macmillan Healthcare Information 1987. p 153-163.
27. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO stud.
28. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414.
29. O'Bryant SE, Waring SC, Cullum M, Hall J, Lactriz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes Scores. Arch Neurol 2008;65:1091-1095.
30. Aisen, P. ADNI and Early AD Trials. Presented at the American Academy of Neurology, April 2009.
31. Tractenberg RE, Weiner MF, Cummings JL, Patterson MB, Thal LJ. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. J Neuropsychiatry Clin Neurosci. 2005;17:51-60.
32. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M et al. Clinical Dementia Rating Training and reliability in multicenter studies: The Alzheimer's Disease Cooperative Study Experience Neurology 1997; 47:1508-1510.
33. Rockwood K, Strang D, MacKnight C, Downer R, Morris JC. Interrater reliability of the Clinical Dementia Rating in a multicenter Trial. J Am Geriatr Soc 2000;48:558-559.